



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Asunercept

Cat. No.:	HY-P99445
CAS No.:	1450882-18-4
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) ^{[1][2][3]} .																
IC₅₀ & Target	CD95L ^{[1][2][3]} .																
In Vitro	<p>Asunercept (APG101; 0-100 µg/mL; preincubation for 30 min) specifically neutralizes the proapoptotic activity of recombinant CD95L in Jurkat A3 cells^[1].</p> <p>Asunercept (0.2, 2, 20 µg/mL; 72 h) is capable of interfering with CD95-induced migration/invasion of glioma cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Jurkat A3 cells (APG293-induced)</td> </tr> <tr> <td>Concentration:</td> <td>0-100 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>30 min (preincubation)</td> </tr> <tr> <td>Result:</td> <td>Completely neutralized APG293-induced apoptosis.</td> </tr> </table> <p>Cell Invasion Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>U87-MG cells (CD95L knockdown; APG293-induced)</td> </tr> <tr> <td>Concentration:</td> <td>0.2, 2, 20 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Blocked APG293 induced invasion of U87 cells (CD95L knockdown).</td> </tr> </table>	Cell Line:	Jurkat A3 cells (APG293-induced)	Concentration:	0-100 µg/mL	Incubation Time:	30 min (preincubation)	Result:	Completely neutralized APG293-induced apoptosis.	Cell Line:	U87-MG cells (CD95L knockdown; APG293-induced)	Concentration:	0.2, 2, 20 µg/mL	Incubation Time:	72 h	Result:	Blocked APG293 induced invasion of U87 cells (CD95L knockdown).
Cell Line:	Jurkat A3 cells (APG293-induced)																
Concentration:	0-100 µg/mL																
Incubation Time:	30 min (preincubation)																
Result:	Completely neutralized APG293-induced apoptosis.																
Cell Line:	U87-MG cells (CD95L knockdown; APG293-induced)																
Concentration:	0.2, 2, 20 µg/mL																
Incubation Time:	72 h																
Result:	Blocked APG293 induced invasion of U87 cells (CD95L knockdown).																

REFERENCES

[1]. Merz C, et al. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. *Anticancer Drugs*. 2015 Aug;26(7):716-27.

[2]. Krendyukov A, et al. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. *Cancer Manag Res.* 2019 Sep 2;11:8095-8100.

[3]. Radujkovic A, et al. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. *Cancers (Basel).* 2020 Dec 8;12(12):3683.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA